Published relevant data on HIV-1 Tat manufactured by DIATHEVA

HIV/AIDS: INTERIM ANALYSIS OF PHASE II TRIAL OF TAT VACCINE IN HIV-INFECTED PATIENTS The results of a 48-weeks interim analysis of a randomized phase II clinical trial suggest that the Tat vaccine can normalize, in a specific and selective manner, the immune functions of HIV-infected patients being treated with antiretroviral drugs.

SNPs Genotyping by High Resolution Melt Analysis

Diatheva is committed to developing kits for SNPs detection in the field of pharmacogenetics and predictive medicine.

Diatheva will hold Biotechnica 2010 - Hannover

5 - 7 / 10 / 2010 Diatheva will take part at the Hannover Fair Trade on Biotechnology and Life Sciences.